Render Target: STATIC
Render Timestamp: 2025-01-21T16:24:10.954Z
Commit: da7e4f2f0d1aed1f1f8e20e4e2ecab8f33cbd595
XML generation date: 2024-08-01 15:25:30.489
Product last modified at: 2025-01-01T09:07:15.471Z
1% for the planet logo
PDP - Template Name: Polyclonal Antibody
PDP - Template ID: *******59c6464

CAD Antibody #11933

Filter:
  • WB
Western Blotting Image 1: CAD Antibody
Western blot analysis of extracts from SW620, MEF, and C6 cells using CAD Antibody.

To Purchase # 11933

Cat. #

Size

11933S
100 µl

Supporting Data

REACTIVITY H M R
SENSITIVITY Endogenous
MW (kDa) 240
SOURCE Rabbit
Application Key:
  • WB-Western Blotting 
Species Cross-Reactivity Key:
  • H-Human 
  • M-Mouse 
  • R-Rat 

Product Information

Product Usage Information

Application Dilution
Western Blotting 1:1000

Storage

Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA and 50% glycerol. Store at –20°C. Do not aliquot the antibody.

Protocol

Specificity / Sensitivity

CAD Antibody recognizes endogenous levels of total CAD protein. This antibody may cross-react with a protein of unknown origin at ~45 kDa in some cell lines.

Species Reactivity:

Human, Mouse, Rat

Source / Purification

Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to residues near the carboxy terminus of human CAD protein. Antibodies are purified by protein A and peptide affinity chromatography.

Background

CAD is essential for the de novo synthesis of pyrimidine nucleotides and possesses the following enzymatic activities: glutamine amidotransferase, carbamoyl-phosphate synthetase, aspartate transcarbamoylase, and dihydroorotase. Thus, the enzyme converts glutamine to uridine monophosphate, a common precursor of all pyrimidine bases, and it is necessary for nucleic acid synthesis (1). In resting cells, CAD is localized mainly in the cytoplasm where it carries out pyrimidine synthesis. As proliferating cells enter S phase, MAP Kinase (Erk1/2) phosphorlyates CAD at Thr456, resulting in CAD translocation to the nucleus. As cells exit S phase, CAD is dephosphorylated at Thr456 and phosphorylated at Ser1406 by PKA, returning the pathway to basal activity (2). Various research studies have shown increased expression of CAD in several types of cancer, prompting the development of pharmacological inhibitors such as PALA. Further studies have identified CAD as a potential predictive early marker of prostate cancer relapse (3).
For Research Use Only. Not For Use In Diagnostic Procedures.
Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
All other trademarks are the property of their respective owners. Visit our Trademark Information page.